

Cannabis Attitudes, Allergies & Patterns of Use in Followers of AAN

April 1, 2021


1

OUR SPEAKERS



Joanna Zeiger, MS, PhD

- Founder & CEO, Canna Research Group
- Olympian & Former World Champion in Triathlon
- Asthmatic




William Silvers, MD

- Clinical Professor at University Colorado Health Sciences School of Medicine
- Faculty Affiliate, CU Center for Bioethics & Humanities

Program Outline

- 1. History of Cannabis use in the US
- 2. Cannabis attitudes and patterns of use among members of the Allergy & Asthma Network (AAN)
- 3. Cannabis and allergies

3





History of Cannabis Use in US

- Cannabis use dates back to the Colonial Era
- American production of hemp (the cannabis plant) was encouraged by the government in the 17th Century for the production of rope, sails, and clothing.
- Domestic production of hemp flourished until after the Civil War, when imports replaced hemp.

Survey of Marijuana Law in the United States: History of Marijuana Regulation in the United States

https://libguides.law.uga.edu/c.php?g=522835&p=3575350 #:~:text=In%20the%20late%2019th%20Century,the%20recr eational%20use%20of%20marijuana.&text=By%201931%2C %2029%20states%20had%20outlawed%20marijuana.

5




History of Cannabis Use in US


- In the late 19th Century, marijuana became a popular ingredient in many medicinal products and was sold openly in pharmacies.
- Marihuana Tax Act of 1937 was the first national regulation of cannabis.
- Cannabis was officially outlawed for any use (medical included) with the passage of the 1970 Controlled Substances Act (CSA).
- Cannabis is a schedule 1 substance federally, but legal in some form in 36 states.

Survey of Marijuana Law in the United States: History of Marijuana Regulation in the United States

https://libguides.law.uga.edu/c.pnb/g=522835&br=3575350#; "text=in%20the%20late%2019t h%20Century.the%20recreational%20use%20of%20marijuana.&text=Bv%201931%2C%2029% 20states%20had%20outlawed%20marijuana.









The Endocannabinoid System 1. Cannabinoid receptors 2. Endocannabinoids **CB** receptors **CB1** receptors Expressed in the CNS CB₁ Psychoactive effects CB2 receptors Expressed in immune system and hematopoietic cells Anandamide 2-Arachidonoylglycerol PSYCHOPHARMACOLOGY 3. Metabolic enzymes that break down the cannabinoids after they are used


9





Cannabis Background: Benefits	
Helpful to cancer patients	
AIDS/HIV patients	
Helps with severe pain	
Helps with seizure disorders	
Can improve sleep, increase calm, decrease anxiety	

Cannabis Background: Adverse effects	
Carifiabis background. Adverse effects	
Hyperemesis syndrome (vomiting)	
Cannabis induced psychosis	
Increased appetite	
Decreased concentration	
Anxiety	
Respiratory & Cardiovascular complications	



Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network

Joanna S. Zeiger, MS, PhD*; William S. Silvers, MD*; Tonya A. Winders, MBA*; Mary K. Hart, RRT*; Robert S. Zeiger, MD, PhD*

*Canna Research Foundation, Boulder, Colorado

Department of Medicine, University of Colorado School of Medicine, Denver, Colorado

[†]Allergy & Asthma Network, Vienna, Virginia

Department of Allergy, Kaiser Permanente Southern California, San Diego, California

15

AAN Study Background I

- In the US, cannabis use is increasing in the general population and various disease populations due to legalization and perceived benefit to combat symptoms of pain, insomnia, and anxiety.
- Cannabis use is poorly studied in allergic/asthmatic patients a group whom route of administration could have broad adverse effects.
- Smoking and vaping cannabis in this population could lead to increased symptoms of cough and wheeze, as well as increased use of asthma medications and exacerbations.
- However, short-term use of cannabis can act as a bronchodilator or cause coughing or wheezing, whereas long-term use could cause increased respiratory symptoms.


AAN Study Background II

- Recruitment was through the AAN via newsletter, social media, webinars.
- Survey was anonymous and was open from May 7, 2020 through September 7, 2020.
- Measured asthma control, asthma quality of life, allergic disease.
- Cannabis questions covered duration and frequency of use, knowledge and attitudes, benefits and adverse effects, routes of administration.
- 489 respondents completed the survey.

17

Results of Survey of Allergy & Asthma Network Members (n=489)

18%	Participants who used cannabis in the past 2 weeks
40.7%	Percent of respondents younger than 50
83.2%	Percent of female respondents
2.5%	Percent of non-cannabis users with cannabis allergy
50.1%	Percent with current asthma
19.2%	Want to discuss cannabis with their allergist
33.9%	Physician asks verbally or on intake about cannabis use



Most common positive effects from cannabis use in current cannabis users

- Helps with sleep
- Less pain
- Calms me down
- Decreased anxiety

Most common adverse effects from cannabis use in current cannabis users			
29.5%	Increased appetite		
21.6%	• Anxiety		
19.3%	• Coughing		
15.9%	Difficulty concentrating		

53.4%	Percent who smoke cannabis
25.0%	Percent who vape cannabis
61.4%	Percent who use edibles
58.0%	Current cannabis users with asthma
50%	Uncontrolled asthmatics who smoked & coughed
19.3%	Reported cough from cannabis use
2.8 points out of 4	 Current cannabis users had more cannabis knowledge points than former (2.6) and never users (1.8) (p<.001




Survey Conclusions


- A minority of AAN respondents currently use cannabis.
- Half of current cannabis users with uncontrolled asthma reported smoking cannabis.
- A minority of allergists inquire about cannabis use.
- A minority of patients want to discuss cannabis with their allergist.
- Positive effects were more common than adverse effects.

23









Association of regular marijuana use alone with chronic respiratory symptoms compared to nonsmokers of any substance

Author	↑ cough	↑ sputum	↑ wheeze	↑ breathlessness
Bloom et al. (1987)	numeric ↑	+	+	ns
Tashkin et al. (1987)	+	+	+	ns
Taylor et al. (2000)	numeric ↑	numeric ↑	numeric ↑	numeric 1
Moore et al. (2004)	+	+	+	ns
Aldington et al. (2007)	+	+	+	NR
Tan et al. (2009)	No significant ↑ in symptoms consistent with COPD			

+ = significant increase compared with nonsmokers of any substance;

ns = not significant; NR = not reported

Habitual marijuana smoking is not associated with COPD

Author	FEV ₁	FVC	FVC	TLC	FRC	RV	SG _{aw}	DLCO
Tashkin et al. (1980)	ns	ns	NR	ns	ns	NR	\	ns
Bloom et al. (1987)	ns	NR	\downarrow	NR	NR	NR	NR	NR
Tashkin et al. (1987)	ns	ns	ns	ns	ns	ns	\downarrow	ns
Sherrill et al. (1991)	↓ *	ns	↓ *	NR	NR	NR	NR	NR
Taylor et al. (2000)	NR	NR	\downarrow	NR	NR	NR	NR	NR
Moore et al. (2004)	NR	NR	ns	NR	NR	NR	NR	NR
Aldington et al. (2007)	ns	NR	ns	ns	ns	ns	\downarrow	ns
Hancox et al. (2010)	ns	trend to ↑	ns	↑	↑	↑	\	ns
Tan et al. (2009)	NR	NR	ns	NR	NR	NR	NR	NR
Pletcher et al. (2012) CARDIA	ns	↑	↑	NR	NR	NR	NR	NR
Kempker et al. (2015) NHANES	ns	↑	\downarrow^{\dagger}	NR	NR	NR	NR	NR

ns = not significant
NR = not reported

↓ = significantly
decreased

↑ = significantly
increased

*p<0.05 with previous
but not current MJ use
(6 yr follow=up)

†p=0.02 with >20 jt-yrs
of MJ use (NHANES
2009-10)

29


Marijuana Smoking is not associated with macroscopic emphysema

	MS (N=75)	MTS (N=91)	TS (N=92)	NS (N=81)
Mean RA950 apical, %	10.8*	10.6*	8.3	8.6
Mean RA950, 3 slices, %	12.3*	10.8	9.6	10.5
Macroscopic emphysema, N (%)	1 (1.3)	15 (16.5)	17 (18.5)	0 (0)

*Significantly different from NS, p<0.05

Aldington S, Williams M, Nowitz M, et al. Effects of cannabis on pulmonary structure, function and symptoms. *Thorax*. 2007;62(12):1058-1063.

Despite abnormal histology, case-control studies suggest no association between habitual marijuana smoking and lung cancer



Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, et al. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. Int J Cancer. 2015;136(4):894-903.

31

Allergens identified in C. sativa in leaves, buds, flowers

10-kDa Can s 3	a ns-LTP (PR-14), in peach, etc
38-kDa	a (PR-5), in grapes, etc
14-kDa	a Profilin (pan-allergen) as Bet v2
23-kDa oxygen- evolvingprotein	Protein for photosynthesis
50-kDa RuBisCo	Rate limiting for photosynthesis
CCD Cross-react. Carbohydrate D	May cross-react with IgE

All allergens reported by: Nayak AP et al. *Ann Allergy Asthma Immunol* 2013; 111:32-37 Except, 10 kDa (nsLTP): Larramendi CH et al. *Int Arch Allergy Immunol* 2013;162:115-122

Cannabis-Fruit-Vegetable Cross-over compared to Pollen-Food Cross-over (OAS)

Sensitizer nsLTP Lipid Transfer protein More severe reactions	Sensitizer Bet v 2 Pan-Allergen Usually mild reactions
Pru p 3 Peach	Pru p 4 Peach
Ara h 9 Peanut	Aara h 5 Peanut
Mal d 3 Apple	Mal d 4 Apple

Van Gasse AL et al. *Clin Chim Acta* 2015;444:54-61 Santos A et al. *Int Arch Allergy* 2011;155:191-201

33

TIME FOR QUESTIONS





